+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Wearable Injectors Market Report and Forecast 2023-2031

  • PDF Icon


  • 160 Pages
  • July 2023
  • Region: Global
  • Expert Market Research
  • ID: 5855121
The global wearable injectors market attained a value of USD 7.1 billion in 2022, driven by increasing prevalence of chronic diseases and the need for convenient and patient-friendly drug delivery methods. The market is expected to grow at a CAGR of 11.91% during the forecast period of 2023-2031 to attain a value of USD 19.4 billion by 2031.

Wearable Injectors: Introduction

Wearable injectors, also known as wearable infusion devices or patch pumps, are innovative medical devices designed to deliver medication or therapeutic substances through the skin into the body. These devices are typically worn on the body, providing a convenient and portable method of drug administration. They offer several uses and benefits in the healthcare field.

The benefits of wearable injectors include:

  • Improved Patient Adherence: Wearable injectors enhance patient adherence to medication regimens. The convenience and ease of use encourage patients to adhere to their prescribed treatment plans, leading to better health outcomes
  • Precise Drug Delivery: Wearable injectors provide precise and controlled drug delivery, ensuring accurate dosing and minimizing the risk of errors. This promotes therapeutic effectiveness and reduces the potential for under or overdosing
  • Reduced Needle Anxiety: For patients who experience needle anxiety or fear, wearable injectors offer a less intimidating method of drug administration. They eliminate the need for frequent needle injections, making the process more tolerable and reducing patient discomfort
  • Flexibility and Mobility: Wearable injectors offer increased flexibility and mobility compared to traditional injection methods. Patients can wear the device discreetly under clothing and carry out their daily activities without interruption, allowing for a more active and unrestricted lifestyle
  • Monitoring and Connectivity: Some wearable injectors come equipped with monitoring features and connectivity capabilities. These devices can track medication usage, provide reminders for dosing, and transmit data to healthcare professionals for remote monitoring. This enhances patient management and enables healthcare providers to intervene if necessary
It is important to note that the selection, use, and management of wearable injectors should be guided by healthcare professionals and manufacturers' instructions. Patients should receive proper training on device usage and adhere to prescribed treatment protocols. Regular follow-up and monitoring are necessary to ensure optimal therapeutic outcomes and safety.

Wearable Injectors Market Segmentations

The market can be categorised into type, therapy, end user, and region.

Market Breakup by Type

  • On-Body Injectors
  • Off-Body Injectors

Market Breakup by Therapy

  • Oncology
  • Autoimmune Disease
  • Diabetes
  • Cardiovascular Disease
  • Others

Market Breakup by End User

  • Hospitals
  • Diagnostic Centres
  • Home Care
  • Others
Wearable Injectors Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Wearable Injectors Market Overview

The wearable injectors market has witnessed significant growth and is projected to continue expanding in the coming years. Several factors contribute to the positive market scenario.

One of the key drivers of market growth is the increasing prevalence of chronic diseases and the growing need for efficient and convenient drug delivery methods. Conditions such as diabetes, autoimmune diseases, cancer, and hormonal disorders require regular administration of medications or therapeutic substances. Wearable injectors offer a portable and user-friendly solution, enabling patients to self-administer medications at home or on-the-go, reducing the need for frequent visits to healthcare facilities.

Moreover, technological advancements in wearable injectors have played a crucial role in market expansion. Manufacturers are introducing innovative features such as programmable dosing, connectivity capabilities, and integration with digital health platforms. These advancements enhance patient convenience, medication adherence, and real-time monitoring, driving the adoption of wearable injectors in both clinical and home healthcare settings.

Furthermore, the shift towards personalized medicine and targeted therapies has fueled market demand for wearable injectors. These devices allow for precise and controlled drug delivery, enabling tailored treatment regimens based on individual patient needs. Wearable injectors offer the flexibility to deliver medications with varying dosages and infusion rates, supporting personalized therapy plans and optimizing treatment outcomes.

Key Players in the Global wearable injectors Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the wearable injectors market are as follows:
  • Amgen
  • Becton
  • Dickinson and Company
  • Dexcom, Inc
  • Enable Injections
  • Insulet Corporation
  • Sensile Medical
  • Tandem Diabetes Care
  • Ypsomed
  • Johnson & Johnson Services
  • F. Hoffmann-La Roche Ltd
  • Unilife Corporation
  • SteadyMed Therapeutics
  • Insulet Corporation
  • CeQur SA
*The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Wearable Injectors Market Overview
3.1 Global Wearable Injectors Market Historical Value (2016-2022)
3.2 Global Wearable Injectors Market Forecast Value (2023-2031)
4 Global Wearable Injectors Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Global Wearable Injectors Market Segmentation
5.1 Global Wearable Injectors Market by Type
5.1.1 Market Overview
5.1.2 On-Body Injectors
5.1.3 Off-Body Injectors
5.2 Global Wearable Injectors Market by Therapy
5.2.1 Market Overview
5.2.2 Oncology
5.2.3 Autoimmune Disease
5.2.4 Diabetes
5.2.5 Cardiovascular Disease
5.2.6 Others
5.3 Global Wearable Injectors Market by End User
5.3.1 Hospitals
5.3.2 Diagnostic Centers
5.3.3 Home Care
5.3.4 Others
5.4 Global Wearable Injectors Market by Region
5.4.1 Market Overview
5.4.2 North America
5.4.3 Europe
5.4.4 Asia Pacific
5.4.5 Latin America
5.4.6 Middle East and Africa
6 North America Wearable Injectors Market
6.1 Market Share by Country
6.2 United States of America
6.3 Canada
7 Europe Wearable Injectors Market
7.1 Market Share by Country
7.2 United Kingdom
7.3 Germany
7.4 France
7.5 Italy
7.6 Others
8 Asia Pacific Wearable Injectors Market
8.1 Market Share by Country
8.2 China
8.3 Japan
8.4 India
8.6 Australia
8.7 Others
9 Latin America Wearable Injectors Market
9.1 Market Share by Country
9.2 Brazil
9.3 Argentina
9.4 Mexico
9.5 Others
10 Middle East and Africa Wearable Injectors Market
10.1 Market Share by Country
10.2 Saudi Arabia
10.3 United Arab Emirates
10.4 Nigeria
10.5 South Africa
10.6 Others
11 Regulatory Framework
11.1 Regulatory Overview
11.1.1 US FDA
11.1.2 EU EMA
11.1.5 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Amgen
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Becton
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Dickinson and Company
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Dexcom, Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Enable Injections
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Insulet Corporation
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Sensile Medical
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Tandem Diabetes Care
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Ypsomed
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Johnson & Johnson Services
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 F. Hoffmann-La Roche Ltd
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Unilife Corporation
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 SteadyMed Therapeutics
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Insulet Corporation
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 CeQur SA
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
18 Wearable Injectors - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
  • *Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Amgen
  • Becton
  • Dickinson and Company
  • Dexcom, Inc.
  • Enable Injections
  • Insulet Corporation
  • Sensile Medical
  • Tandem Diabetes Care
  • Ypsomed
  • Johnson & Johnson Services
  • F. Hoffmann-La Roche Ltd
  • Unilife Corporation
  • SteadyMed Therapeutics
  • Insulet Corporation
  • CeQur SA



Table Information